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Azole antifungals are essential and effective drugs in treating a variety of superficial and 
systemic mycoses in veterinary species. Their activity is attributable to inhibition of fungal 
ergosterol by targeting cytochrome P450-dependent sterol 14α-demethylase. The most 
commonly used azoles in small animal veterinary medicine are itraconazole (ITZ), fluconazole 
(FCZ), and ketoconazole (KTZ). Owing to its greater selectivity for fungal ergosterol over 
mammalian cholesterol, ITZ has fewer adverse effects than KTZ. Additionally, it has a broader 
spectrum of activity than both KTZ and FCZ. For this reason, ITZ is used to treat a variety of 
fungal infections in dogs and is the treatment of choice for canine blastomycosis, a severe 
systemic mycosis endemic in the Midwest. Despite its efficacy, ITZ is associated with a number 
of adverse reactions including hepatotoxicity. The mechanism of this toxicity is unknown. 
As with many drugs, oxidative damage may play an important role in ITZ-associated 
toxicity. In rodent studies, ITZ administration increases levels of myeloperoxidase and nitric 
oxide and decreases levels of hepatic glutathione (GSH) and other antioxidants. Based on this, 
antioxidant therapy could potentially prevent or treat ITZ-associated hepatotoxicity. Antioxidant 
hepatoprotectants are commonly used for a variety of liver diseases in veterinary medicine. 
These include GSH precursors like S-adenosylmethionine (SAMe) and N-acetylcysteine (NAC) 
and other antioxidants including silybin, vitamin E, and vitamin C. However, no studies have 
investigated the efficacy of this practice and scientific evidence is needed to provide a basis for 
their use. A reliable in vitro model to establish these principles is required prior to testing 
compounds in animal subjects.         
The objective of this work was to develop an in vitro primary canine hepatocyte model of 
ITZ-associated hepatotoxicity and evaluate the effect of GSH using the model. We hypothesized 
that GSH would ameliorate ITZ-associated hepatocyte death in vitro. The results demonstrate 
dose and time-dependent cytotoxicity of cryopreserved primary canine hepatocytes exposed to 
ITZ. Pre-incubation with GSH caused a dose-dependent decrease in toxicity. This study 
establishes primary canine hepatocytes as an appropriate in vitro model for ITZ-associated 
toxicity. GSH pre-treatment partially ameliorates the toxic effect, suggesting a possible role for 
GSH and oxidative stress in the pathogenesis of toxicity. These findings support continued 
investigation into other antioxidants as prevention and/or treatment for ITZ-associated 
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CHAPTER 1: LITERATURE REVIEW 
Introduction  
 Superficial and systemic mycoses are common infections in veterinary species, resulting 
in significant morbidity, mortality, and cost. A wide variety of antifungal drugs have been 
developed and used to treat superficial cutaneous infections such as malasseziosis and 
dermatophytosis, systemic mycoses such as blastomycosis and histoplasmosis, and mycoses 
caused by opportunistic fungi (Greene, 2012). The first effective systemic antifungals, 
griseofulvin and amphotericin B, were discovered in the 1960s (Smith, 1990). For a time, 
griseofulvin was the drug of choice for dermatophytosis in both human and veterinary medicine, 
but its use has gradually been replaced by the addition of oral azole antifungals to the market in 
the 1980s (Maertens, 2004). Similarly, the use of amphotericin B, which is associated with 
nephrotoxicity, decreased significantly after introduction of the azoles (Davis et al., 2018). In 
general, azoles are better tolerated and have a wider spectrum of action than the early antifungal 
drugs. 
 Itraconazole (ITZ), a triazole antifungal, is used to treat many types of fungal infections. 
It is the treatment of choice for canine blastomycosis, for which it has a reported cure rate of 
between 54-90% and a relapse rate of 18-20% (Legendre et al., 1996; Mazepa et al., 2011). 
Blastomycosis is endemic is certain areas of the United States, including the Ohio, Missouri, and 
Mississippi River valleys (Furcolow et al., 1970). A study in Illinois documented a mean 
estimated incidence of canine blastomycosis from 2001-2007 as 62.5 cases/100,000 dogs/year 
(Herrmann et al., 2011). In the same study, the mean estimated incidence in humans in Illinois 
was 7.5 cases/1 million persons/year. Trends in incidence and distribution were similar for 
humans and dogs, indicating that dogs may be a good sentinel species for human blastomycosis. 
Because blastomycosis causes significant morbidity and mortality in dogs and other mammals, 
including human beings, a safe and effective treatment is essential. Despite its efficacy, ITZ is 
associated with a number of adverse reactions, including anorexia, lethargy, vomiting, and 
hepatotoxicity (Legendre et al., 1996; Mazepa et al., 2011). Although drug discontinuation 
generally results in reversal of these changes, switching antifungal drugs can negatively impact 




 Hepatoprotectants are commonly used to treat liver enzyme elevation due to ITZ 
administration in dogs. These include S-adenosyl-L-methionine (SAMe) and N-acetylcysteine, 
which are important in the synthesis and maintenance of cellular glutathione (GSH) levels 
(Bottiglieri, 2002; Lauterburg et al., 1983). GSH is an endogenous antioxidant critical for cell 
survival (Yuan and Kaplowitz, 2009). Other antioxidants such as silybin, vitamin E, and vitamin 
C are also used in dogs with clinical changes compatible with ITZ-associated hepatotoxicity. 
Many of these products are expensive and can lead to inappetence, so scientific evidence is 
needed to provide a basis for their use. The objective of the work presented in Chapter 2 is to 
evaluate the effect of GSH treatment on ITZ-associated hepatocyte toxicity using an in vitro 
primary canine hepatocyte model. 
 
The Azole Antifungals  
 Azole antifungals are commonly utilized to treat a variety of fungal infections in dogs, as 
outlined above. There are two main groups of azoles, the imidazoles and the triazoles. These two 
groups have the same mechanism of action but differ in their structure and spectrum of activity 
(Table 1.1).  
Mechanism of action of azole antifungals  
 Azoles target the fungal cell membrane by inhibiting the formation of ergosterol. 
Ergosterol is the primary sterol found in the fungal cell membrane, in contrast to mammalian 
cells that utilize cholesterol. Specifically, azoles inhibit the cytochrome P450-dependent (CYP) 
lanosterol 14α-demethylase (CYP51). Selective toxicity of a particular azole is dependent on its 
preferential binding of fungal CYP over mammalian CYP. Azoles inhibit CYP51 by binding 
nitrogen to the heme ferric core, preventing the demethylation of 14α-methylsterols and 
decreasing ergosterol synthesis (Davis et al., 2009). These perturbations lead to altered 
membrane fluidity and function, changes in membrane bound enzymatic activity, and disordered 
chitin synthesis (Vanden Bossche, 1985). At clinically achievable concentrations, azoles are 
fungistatic. Certain azoles, including miconazole, econazole, and clotrimazole, also alter 
membrane lipid organization and function, which may explain their antimicrobial activity against 






 The imidazoles have an azole ring containing two nitrogen atoms and include 
ketoconazole (Figure 1.1), clotrimazole, miconazole, and enilconazole (Davis et al., 2009). 
Clotrimazole, miconazole, and enilconazole are restricted to topical use for a variety of reasons. 
Oral clotrimazole is poorly tolerated and the pharmacokinetics are unpredictable, likely due to 
induction of hepatic microsomal enzymes (Burgess and Bodey, 1972). Miconazole has poor oral 
absorption as well as significant vehicle-related, adverse histamine-mediated effects in the 
parenteral form (Wade et al., 1979), which is no longer available in the United States. 
Miconazole and clotrimazole are mainly used for superficial mycoses, including dermatophytosis 
and malasseziosis. Enilconazole, on the other hand, is only approved for use in the U.S. as an 
environmental decontaminant in poultry facilities. However, it has been effective in topical 
treatment of cats infected with Microsporum canis (Hnilica and Medleau, 2002) and dogs with 
nasal aspergillosis (Sharp et al., 1993). Of the imidazoles, ketoconazole is the only drug 
approved for systemic use.   
Ketoconazole 
 Ketoconazole (KTZ) was approved by the Food and Drug Administration (FDA) as a 
systemic antifungal drug in 1981 (Maertens, 2004). KTZ requires an acidic environment for 
absorption. Because feeding stimulates gastric acid secretion, absorption is increased after a 
meal. For nearly a decade, KTZ was the only systemic azole antifungal drug available. In human 
medicine, the use of KTZ has been largely replaced by the safer triazoles; in veterinary medicine, 
however, KTZ is still frequently used due to its efficacy and lower cost. KTZ is effective against 
superficial fungi like dermatophytes, Candida, and Malassezia pachydermatis as well as 
systemic Candida spp., Blastomyces dermatitidis, Histoplasma capsulatum, and Coccidioides 
immitis. It has limited efficacy against Cryptococcus neoformans, Sporothrix schenkii, and 
Aspergillus sp. (Davis et al., 2009).  
In addition to inhibiting fungal CYPs, ketoconazole is a strong inhibitor of mammalian 
CYPs (Maurice et al., 1991; Back and Tija, 1991), including those responsible for drug 
metabolism and androgen and cortisol synthesis (de Coster et al., 1988). For this reason, 
ketoconazole administration may result in drug interactions (Hugnet et al., 2007; Mayer et al., 
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2008), testosterone suppression, and basal cortisol suppression in dogs (Willard et al., 1986). 
KTZ’s inhibition of mammalian CYPs is sometimes exploited for other uses in veterinary 
medicine. For example, co-administration of KTZ with cyclosporine in dogs causes CYP 
inhibition, which can lower the dose and cost of cyclosporine therapy (Dahlinger et al., 1998). 
KTZ is also effective at reducing plasma cortisol levels in dogs with hyperadrenocorticism 
owing to its inhibition of steroid synthesis, although alternate therapies are preferred (Feldman et 
al., 1990). Vomiting, anorexia, diarrhea, and lethargy are the most common side effects of 
ketoconazole administration in dogs, occurring in approximately 15% of patients (Mayer et al., 
2008). In this retrospective study, liver enzyme elevations occurred rarely but were not 
associated with icterus. KTZ is also associated with hepatotoxicity in man (Lewis, et al., 1984; 
Duarte et al., 1984), in which the incidence of KTZ-associated hepatotoxicity is similar to that of 
ITZ (Lo Re et al., 2016). 
 
Figure 1.1. Chemical structure of KTZ (Source: https://en.wikipedia.org/wiki/Ketoconazole) 
Triazoles  
 The triazoles have an azole ring containing three nitrogen atoms and include ITZ, 
fluconazole (FCZ), voriconazole, and posaconazole (Figure 1.2). Triazoles are more specific for 
fungal CYPs and have considerably less effect on mammalian steroid synthesis than the older 
imidazoles (Davis et al., 2009). As there are typically fewer side effects, systemic triazoles are 
generally preferred over KTZ.  
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 ITZ and FCZ are the most commonly used triazoles in veterinary medicine. Voriconazole 
and posaconazole are newer generation triazoles used for severe or drug resistant infections 
(Greene, 2012).  
Fluconazole 
 FCZ was the first triazole drug approved for use in the U.S. It is small, water-soluble, has 
low protein binding, and is eliminated primarily through the kidneys (Davis et al., 2018). 
Because of these properties, FCZ readily distributes throughout the body, penetrating aqueous 
sites including cerebrospinal fluid (CSF), aqueous humor, and synovial fluid (Felton et al., 
2014). FCZ is recommended for treatment of central nervous system (CNS) mycoses in dogs and 
cats due to its small size and low protein binding, which allow it to effectively cross the blood-
brain-barrier (Malik et al., 1992; O’Toole et al., 2003). Accumulation of FCZ in the CSF does 
not equate to parenchymal penetration due to limited rates of diffusion. In comparison, ITZ is 
large, highly lipophilic, and has a high proportion that is bound to protein. Its lipophilicity allows 
it to cross the blood-brain-barrier; however, unlike FCZ, ITZ is a substrate for the P-glycoprotein 
efflux pump so it is efficiently removed from the CNS (Felton et al., 2014). FCZ is frequently 
used to treat dermatophytosis and is also effective in treating systemic mycoses, including those 
caused by Candida sp., C. neoformans, B. dermatitiditis, and H. capsulatum. It is less effective 
in treating Aspergillus sp. and Penicillium sp. but has been used to treat these infections in dogs 
(Davis et al., 2009). Successful treatment of blastomycosis may require higher doses for FCZ for 
a longer treatment period when compared to ITZ (Mazepa et al., 2011; Pappas et al., 1997).  
Itraconazole  
 ITZ was approved for use by the FDA in 1992 (Maertens, 2004) and has since largely 
replaced the use of KTZ in human medicine. ITZ is highly lipophilic and the original 
encapsulated formulation requires an acidic environment, like KTZ, for absorption. Liquid 
formulations complexed with hydroxypropyl-β-cyclodextrin were subsequently approved for use 
with better absorption profiles (Boothe et al., 1997; Barone et al., 1998). Intravenous ITZ 
achieves high steady state plasma concentrations faster than oral ITZ (Maertens, 2004) but is no 
longer available in the United States. 
ITZ has several benefits when compared to KTZ. First, it more selectively inhibits fungal 
CYPs (Vanden Bossche et al., 1987; Vanden Bossche et al., 1990). Early studies demonstrated a 
6 
 
lack of inhibition of mammalian CYPs in the testis, adrenal glands, and liver in vitro (Vanden 
Bossche et al., 1990) and in the hypothalamic-pituitary-adrenal axis in dogs (Phillips et al., 
1987). Subsequent studies have demonstrated that ITZ is indeed a mammalian CYP inhibitor 
(Back and Tija 1991; Florea et al., 2003; Isoherranan et al., 2004), although less significantly 
than KTZ. Depression of steroid synthesis is not observed clinically and drug interactions are 
less common in dogs treated with ITZ. Like with KTZ, the most common side effects are 
anorexia, vomiting, diarrhea, lethargy, and elevated ALT with cutaneous vasculitis and 
ulceration occurring less frequently (Legendre et al., 1996).  
 ITZ is effective in treating infections with numerous fungi, including dermatophytes, 
Candida sp., C. neoformans, Aspergillus sp., Malassezia sp., S. schenckii, B. dermatitiditis, and 
H. capsulatum (Van Cutsem et al., 1987a; Davis et al., 2009). It has a broader spectrum of 
activity than both FCZ (Van Cutsem et al., 1990) and KTZ (Van Cutsem et al., 1987a) and is 
more efficacious than KTZ in treating a variety of fungal infections in animal models (Van 
Cutsem et al., 1987b; Van Cutsem et al., 1987c). Historically, amphotericin B was the treatment 
of choice for canine blastomycosis, but due to the potential for nephrotoxicity, azole antifungals 
are now preferred (Legendre et al., 1996). In a retrospective study comparing the efficacy of ITZ 
and FCZ in the treatment of canine blastomycosis, FCZ had a similar efficacy but required an 
average of 45 additional days of treatment (Mazepa et al., 2011). Additionally, B. dermatitidis is 
more susceptible to ITZ in vitro than FCZ and KTZ (Chapman et al., 1997). For these reasons, 
ITZ is the treatment of choice for canine blastomycosis with a reported cure rate of between 54-
90% and a relapse rate of 18-20% (Legendre et al., 1996; Mazepa et al., 2011).  
Voriconazole  
 Voriconazole is a newer triazole antifungal with a similar structure to FCZ. Its spectrum 
of activity is similar to that of ITZ (Davis et al., 2018), although it is more potent (Greer, 2003). 
Voriconazole is fungicidal against Aspergillus sp., fungistatic against Candida sp., and displays 
in vitro efficacy against C. neoformans, B. dermatitidis, and H. capsulatum (Greer, 2003). In 
people, voriconazole is indicated for treatment of aspergillosis and other opportunistic fungi not 
susceptible to other antifungals (Greer, 2003). Voriconazole is small with intermediate protein 
binding and lipophilicity, which facilitates its movement across both the blood-CSF and blood-
brain barrier (Felton et al., 2014). For these reasons, voriconazole can be used for CNS infections 
in veterinary patients (Bentley et al., 2011; Raghu and Reagh, 2018). It is the treatment of choice 
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for CNS aspergillosis in man (Felton et al., 2014).  Adverse neurologic events have occurred in 
cats administered voriconazole orally (Quimby et al., 2010), which may be due to an extremely 
long half-life after short term oral administration (Vishkautsan et al., 2016). While effective, the 
therapeutic range is narrow in cats, so the utility of this drug is limited in feline patients 
(Vishkautsan et al., 2016).   
Posaconazole  
 The newest triazole antifungal, posaconazole, has a similar structure to ITZ. It is used for 
invasive fungal infections like Aspergillus sp. and, unlike other azoles, has activity against 
Zygomycetes (Davis et al., 2018). Currently, the only FDA approved formulation in animals is 
the topical otic suspension Posatex®. Oral posaconazole has been used to safely treat 
disseminated Aspergillus in dogs; however, relapse was common (Corrigan et al., 2016). In a 
single case report, oral posaconazole successfully cured orbital aspergillosis in a Persian cat after 





Figure 1.2. Chemical structure of select imidazoles (Source: https://www.wikipedia.org/)   
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Table 1.1. Summary of azole antifungals 
Azole Route Spectrum of Activity Species Product Indication 
Imidazoles 
Ketoconazole PO Dermatophytes, Candida, 
Malassezia, Blastomyces, 
Histoplasma, Coccidioides  
D, C Nizoral Systemic 
mycoses 
Clotrimazole T Dermatophytes, 
Aspergillus, Candida, 
Malassezia 






Miconazole T Dermatophytes, Candida 
Malassezia 





Enilconazole T Dermatophytes, 
Aspergillosis 








Blastomyces, Histoplasma,  
D,C Diflucan CNS mycoses 














D Vfend CNS mycoses, 
resistant 
aspergillosis 
Posaconazole PO, T Zygomycetes, Aspergillus D, C Posatex (otic)*, Noxafil  Resistant 
aspergillosis, 
zygomycetosis 
 PO=by mouth, IV=intravenous, T=topical, D=dogs, C=cats, *=FDA approved for use in animals 
 
ITZ Metabolism 
 ITZ is used to treat a number of systemic mycoses, but its metabolism and toxic 
mechanisms in animals are poorly understood. In humans and animals, ITZ is extensively 
metabolized by hepatic enzymes into more than 30 metabolites (Heykants et al., 1987). The main 
metabolite, hydroxy-ITZ (OH-ITZ) has similar antifungal activity and higher peak plasma levels 
than ITZ after single dose oral administration in healthy adults (Heykants et al., 1989). In man, 
co-administration with phenytoin, a potent CYP3A4 inducer, dramatically increases the 
clearance of ITZ and OH-ITZ (Ducharme et al., 1995). Similarly, serum ITZ levels are markedly 
decreased in patients receiving concurrent rifampicin, carbamazepine (Tucker et al., 1992), or 
phenobarbital (Bonay et al., 1993), other known CYP inducers. The increased clearance and 
decreased serum ITZ levels in the presence of CYP3A4 inducers implicates this enzyme in the in 
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vivo metabolism of ITZ. The role of CYP3A4 is further supported by the work of Isoherranen et 
al. (2004) who showed that ITZ is efficiently metabolized into OH-ITZ by heterologously 
expressed CYP3A4 Supersomes. In this study, additional unknown metabolites were identified 
as keto-ITZ and N-desalkyl-ITZ (ND-ITZ) by mass spectrometry. The group proposed a 
sequential pathway of ITZ hydroxylation into OH-ITZ followed by oxidation into keto-ITZ and 
subsequent oxidation into ND-ITZ (Figure 1.3). They also demonstrated that the metabolism of 
midazolam, a CYP3A4 substrate, is decreased in the presence of ITZ or OH-ITZ, showing that 
ITZ and its metabolites are competitive inhibitors of CYP3A4. In further support of ITZ as a 
CYP inhibitor, ITZ inhibits cyclosporine metabolism both in vitro (Back and Tija, 1991) and 
clinically (Florea et al., 2003). After oral administration in man, ITZ exhibits nonlinear, dose-
dependent kinetics as demonstrated by disproportionately increased plasma concentrations, area 
under the curve (AUC), and elimination half-life after multiple doses (Van Peer et al., 1987; 
Hardin et al., 1988). These nonlinear, dose-dependent pharmacokinetics could be explained by 
competitive inhibition of ITZ metabolism by its own metabolites. A similar metabolic pathway 
for ITZ is suspected in dogs as OH-ITZ has been identified in canine serum after oral 
administration of ITZ (Yoo et al., 2002), but the specific enzyme responsible for its metabolism 
has not been established. 
 There are significant species differences in CYP enzymes between man and dog. Canine 
orthologs to human CYPs containing homologous genes may have a similar function or display 
variations in substrate specificity and enzyme activity (Martinez et al., 2013). Two CYP3A 
enzymes have been identified in dogs, CYP3A12 (Ciaccio et al., 1991) and CYP3A26 (Fraser et 
al., 1997). The amino acid sequences of these enzymes are 96% identical (Fraser et al., 1997). 
They are differentially expressed, with CYP3A26 comprising 75.2% of hepatic CYP3A and 
CYP3A12 comprising 99.8% of duodenal CYP3A (Mealey et al., 2008). Canine CYP3A12 also 
shares 79.8% of its amino acid sequence with human CYP3A4 (Ciaccio et al., 1991), one of four 
members of the human CYP3A family. For this reason, canine CYP3A12 is considered an 
ortholog of human CYP3A4. It is possible that CYP3A26 is also an ortholog for CYP3A4 or for 
another human CYP3A enzyme, although this has not been investigated. Despite their relation, 
canine CYP3A12 and human CYP3A4 enzymes may not share the same substrates. For example, 
midazolam, which is primarily metabolized by CYP3A4/CYP3A5 in man (Wandel et al., 1994) 




Figure 1.3. Proposed sequential metabolism of ITZ by CYP3A4 (Isoherranen et al., 2004). 
 
ITZ-Associated Adverse Drug Reactions 
Administration of ITZ is associated with multiple side effects in dogs, including nausea, 
vomiting, lethargy, anorexia, and ulcerative dermatitis with vasculitis (Legendre et al., 1996; 
Mazepa et al., 2011). These adverse drug reactions (ADR) may occur with or without concurrent 
hepatotoxicity, which is often asymptomatic but can lead to serious illness.  
Hepatotoxicity 
Hepatotoxicity, as measured by elevated serum alanine transferase (ALT) activity, is a 
serious and potentially life-threatening ADR that occurs in 8-42% of dogs, depending on the 
dose and duration of therapy (Legendre et al., 1996; Mazepa et al. 2001). The majority of these 
cases are asymptomatic, although the overall incidence of clinical hepatotoxicity in dogs is 
unknown. Based on clinical experience, clinical hepatotoxicity does occur and it is likely that 
intervention by veterinarians prevents the many of these cases. There is, however, considerably 
more data on the occurrence of hepatotoxicity in human patients receiving azole antifungal 
therapy.  
Wang et al. (2010) conducted a systematic review and meta-analysis of hepatotoxicity 
caused by antifungals used to treat invasive fungal infections. In the 39 randomized controlled 
trials included in the study, there was a pooled risk of 1.5% in patients treated with ITZ of 
developing abnormal liver function tests necessitating discontinuation of treatment. The pooled 
risk of developing liver enzyme elevations that did not require treatment alterations in patients 
treated with ITZ was 17.4%. This is compatible with other smaller case studies where the 
majority of patients with elevated liver enzymes are asymptomatic (Restrepo et al., 1986; 
Perissinotti and Marini, 2018). Hepatotoxicity is generally reversible with discontinuation of 
therapy (Benitez and Carver, 2019), but can sometimes lead to death (Tuccori et al., 2008). The 
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clinical and histopathologic pattern is primarily cholestatic (Lavrijsen et al., 1992; Legras et al., 
2002; Jiminez-Saenz et al., 2004; Adriaenssens et al., 2014) although panlobular necrosis may 
occur with long-term pulse therapy (Tuccori et al., 2008; Srebrnik et al., 2005).  
The occurrence of hepatotoxicity in dogs has been reported in multiple veterinary studies, 
although clinical disease is poorly documented. In Legendre et al.’s (1996) prospective study of 
112 dogs with blastomycosis, 8% of those receiving the lowest recommended dose of ITZ (5 
mg/kg/day) had mild elevations in ALT (76 to 200 IU/L) and 4% had severe elevations in ALT 
(>400 IU/L). At the highest recommended dose of 10 mg/kg/day, 43% had mild, 10% had 
moderate (201-400 IU/L), and 8% had severe elevations in ALT. Normal serum ALT was 
categorized as 20 to 75 IU/L. In another, retrospective, study of 31 dogs treated with ITZ for 
blastomycosis, increases in ALT were identified in 6 of 23 dogs (26%). Treatment was 
discontinued in 1 of 23 dogs due to progressive ALT elevations (Mazepa et al., 2011). Wilson et 
al. (2018) recorded elevated ALT in up to 42% of dogs receiving ITZ therapy for histoplasmosis. 
In the majority of cases, liver enzyme elevations are not accompanied by clinical signs or 
dysfunction and the medication is continued; in others, progressive ALT elevations necessitate 
discontinuation of the drug. This is similar to what occurs in human patients experiencing 
hepatotoxicity. 
Other Adverse Drug Reactions  
 Other ADRs in dogs associated with oral ITZ administration include anorexia, lethargy, 
vomiting, diarrhea, pollakiuria, elevated blood urea nitrogen (BUN), skin ulceration associated 
with vasculitis, flaky skin, and hair loss (Legendre et al., 1996). These changes can occur with or 
without concurrent elevations in ALT. In the study by Legendre et al. (1996), the occurrence of 
non-hepatic ADRs was dose dependent. Approximately 30% of dogs given the highest dose (10 
mg/kg/day) experienced a non-hepatic ADR, including anorexia (14.9%), skin ulceration (7.5%), 
lethargy (4.5%), diarrhea (3.0%), increased BUN (3.0%), vomiting (2.8%), or flaky skin and hair 
loss (1.5% each). At the lowest, and currently recommended, dose (5 mg/kg/day), 7.5% of dogs 
experienced non-hepatic ADRs, including anorexia (2.5%), vomiting (2.5%), or pollakiuria 
(2.5%). As treatment efficacy was similar between the two doses, the lower dose is 
recommended. Similar gastrointestinal and cutaneous ADRs are reported in man (Amichai and 




Mechanisms of Azole Hepatotoxicity  
All azoles have the potential to cause hepatotoxicity. Toxic mechanisms are, however, 
poorly understood. Hepatotoxicity caused by KTZ is best characterized in experimental animal 
models. As they are a similar class of drug, details about hepatotoxic mechanisms of KTZ can be 
used as a guide to investigate similar mechanisms of ITZ hepatotoxicity.  
Proposed Mechanisms of KTZ Hepatotoxicity  
Like ITZ, metabolism of KTZ by hepatic enzymes produces several metabolites. The 
major metabolite that accumulates in the liver of mice is N-deacetyl ketoconazole (DAK) 
(Whitehouse et al., 1990). Using human liver microsomes, Fukami et al. (2016) demonstrated 
that KTZ is hydrolyzed into DAK by human arylacetamide deacetylase (AADAC) in the liver. In 
both rats (Rodriguez et al. 1999) and humans (Fukami et al., 2016), DAK is subsequently 
metabolized by microsomal flavin-containing monooxygenases (FMO) into N-hydroxy-DAK. N-
hydroxy-DAK is susceptible to further oxidation by FMOs, which may lead to accumulation of 
toxic dialdehydes (Rodriguez and Acosta, 1997b; Rodriguez et al. 1999).  
Rodriguez and Acosta demonstrated that KTZ (1995) and DAK (1997a) are toxic to 
primary rat hepatocytes in a time and concentration dependent manner. DAK was a more potent 
toxin than the parent compound, KTZ. Additionally, the toxicity was increased by addition of n-
octylamine, a positive effector of FMO, and suppressed by methimazole, a competitive substrate 
for FMO. These findings suggest that DAK and subsequent toxic metabolites produced through 
the action of microsomal FMOs may be, in part, responsible for hepatotoxicity observed 
clinically.  
Later studies showed a biphasic in vivo toxicity in rats with an early spike in serum ALT 
after KTZ exposure, which declined after four hours and then subsequently increased at 12 and 
24 hours (Rodriguez and Buckholz, 2003). Consistent with earlier studies, this suggests initial 
injury caused by KTZ and later injury in response to its metabolites.  
Proposed Mechanisms of ITZ Toxicity  
Less is known about mechanisms of ITZ toxicity. In rats, ITZ causes dose-dependent 
cytotoxicity in vitro (Somchit et al., 2002; Somchit et al., 2009) and in vivo (Somchit et al., 2004; 
Somchit et al., 2006). As ITZ is metabolized through hepatic CYP enzymes, Somchit et al. 
utilized CYP inhibitors and inducers to investigate the role of CYPs in development of 
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hepatotoxicity. Rats were pre-treated with phenobarbital, a known CYP inducer, prior to 
isolation of hepatocytes for in vitro exposure to azoles. At the highest concentration of ITZ (1.0 
mM), phenobarbital-induced hepatocytes had significantly higher viability when compared with 
the control (Somchit et al., 2002). In a subsequent in vivo study, rats were treated with either 
phenobarbital or SKF525A, a non-selective CYP inhibitor (Somchit et al., 2006). Similar to their 
2002 in vitro study, they found that CYP induction with phenobarbital reduced hepatotoxicity as 
measured by decreased activities of ALT and γ-glutamyl transferase (GGT) and reduced 
inflammation and necrosis histologically. In contrast, CYP inhibition with SKF525A resulted in 
significantly increased hepatotoxicity as measured by elevated ALT, ALP, and GGT and 
increased amounts of inflammation and necrosis.  
These findings shed light on possible mechanisms of toxicity. First, the protective effect 
of CYP induction suggests that the CYP pathway is not responsible for production of toxic 
metabolites. This is further supported by the deleterious effect of CYP inhibition, implicating 
either a possible role for the parent compound in toxicity or metabolites generated by a non-CYP 
metabolic pathway. For example, FMO-mediated metabolism, similar to that occurring during 
production of toxic metabolites from KTZ, is one possible pathway by which toxic ITZ 
metabolites could be generated. ITZ itself is a CYP inhibitor (Back and Tija 1991; Isoherranen et 
al., 2004; Florea et al., 2003; Somchit et al., 2006), so it is possible that autoinhibition of its own 
metabolizing CYP enzymes over time potentiates toxicity.  
Somchit et al. also compared histologic changes in rats administered increasing doses of 
ITZ. In the 2004 study, rats were administered either a single dose of ITZ or daily dosing for 14 
days. They noted a dose dependent increase in centrilobular and midzonal degeneration with 
focal hepatocellular necrosis, granuloma formation, and biliary hyperplasia in the subchronic 
dosing group. In contrast, rats in the 2006 study were administered ITZ for 4 days and had 
periportal to midzonal necrosis and inflammation. A wide variety of toxicants cause centrilobular 
injury due to the concentration of metabolizing enzymes, including CYPs, in this area. Periportal 
injury, however, is generally caused by direct acting toxicants that do not require 
biotransformation (i.e. phosphorus) (Haschek et al., 2010). Variations in oxygen tension can also 
impact the zonal distribution.  Differences in the lobular pattern between these studies could be 
due to variations in experimental design, including treatment duration (14 days in 2004 study vs 
4 days in 2006 study) and maximum dosage (100 mg/kg/day in 2004 study vs. 200 mg/kg/day in 
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the 2006 study). Centrilobular damage implicates CYP or another enzyme system concentrated 
in this area in producing a toxic metabolite. Given the primarily periportal damage in the 2006 
study, it is possible that the parent compound may also play a role in toxicity prior to 
biotransformation. If conclusions can indeed be drawn about ITZ given what we know about 
KTZ, it is reasonable to speculate that the parent compound may cause periportal damage and 
toxic metabolites produced later may cause centrilobular or periportal damage depending on the 
enzyme system involved. A series of in vivo rodent studies controlling for treatment duration and 
dosage is required to clarify the relationship between toxicity and morphologic alterations in the 
liver.  
 In cases of clinical liver disease in man due to ITZ administration, liver damage may be 
massive (Tuccori et al., 2008; Srebrnik et al., 2005), cholestatic (Lavrijsen et al., 1992; Legras et 
al., 2002; Jiminez-Saenz et al., 2004; Adriaenssens et al., 2014), or both. Massive necrosis 
usually occurs as an idiosyncratic response or due to large doses of drug whereas cholestatic 
injury can be due to either hepatocellular damage or direct damage to the biliary epithelium 
(Haschek et al., 2010). Patterns of liver damage have not been documented in the canine 
literature. The wide variety of alterations in experimental and natural disease likely reflect 
differences in dose, duration, and individual susceptibility.  
Proposed Mechanisms of FCZ Toxicity  
 In the series of studies by Somchit et al. described previously, ITZ experiments were 
conducted in parallel with FCZ exposure. FCZ caused dose- and time-dependent cytotoxicity in 
rat hepatocytes but was significantly less cytotoxic than ITZ (Somchit et al., 2002; Somchit et 
al., 2009). Histologically, FCZ caused only mild hepatocellular degeneration in rats at the 
highest dose (Somchit et al., 2004). In contrast to ITZ, CYP induction with phenobarbital was 
not cytoprotective against FCZ-induced cytotoxicity (Somchit et al., 2002). Because FCZ is 
excreted up to 80% unchanged in the urine (Grant et al., 1990) and does not undergo extensive 
CYP metabolism, this was an expected finding.  CYP inhibition with SKF525A did, however, 
cause increased FCZ associated cytotoxicity (Somchit et al., 2006). Like ITZ and KTZ, the 
mechanism of FCZ hepatotoxicity is unknown, but could be due to toxic effects of the parent 





Oxidative Damage in ITZ-Associated Hepatotoxicity  
 As with many drugs, oxidative damage may play an important role in ITZ-associated 
hepatotoxicity. Sozen et al. (2014) showed that rats administered oral ITZ had increased hepatic 
myeloperoxidase, an enzyme produced by neutrophils that is responsible for conversion of 
hydrogen peroxide to hypochlorous acid, a potent cytotoxic and oxidizing agent (Kumar et al., 
2015b) and nitric oxide, a free radical that can also be converted into the highly oxidizing 
peroxynitrite anion (Kumar et al., 2015a). They also had decreased activities of hepatic 
superoxide dismutase and glutathione peroxidase, which are essential antioxidants responsible 
for scavenging free radicals (Kumar et al., 2015a) and increased hepatocellular degeneration, 
inflammation, and necrosis.     
 Oxidative stress and hepatocellular degeneration and necrosis have also been documented 
in pregnant rats and their fetuses administered ITZ at different stages of gestation (El-Shershaby 
et al., 2015). This study showed that both dams and fetuses had dose dependent increases in 
hepatic malondialdehyde, the principal product of lipid peroxidation and a common marker of 
oxidative stress (Del Rio et al., 2005). Dams and fetuses also had decreased levels of reduced 
hepatic GSH. As the major intracellular antioxidant (Yuan and Kaplowitz, 2009), decreased 
GSH is an indirect marker of elevated oxidative stress. Lastly, dams had decreased hepatic 
catalase, another enzyme important in reducing oxidative damage (Kumar et al., 2015a). 
   
The Role of Glutathione in Azole-Associated Hepatotoxicity  
 GSH is an endogenous hepatic antioxidant critical to cell survival. As the most powerful 
reducing agent in the cell, it is essential for maintenance of redox potential and cell signaling 
(Yuan and Kaplowitz, 2009). GSH is an essential cofactor acting as a hydrogen donor for 
glutathione peroxidase, which, in turn, reduces hydrogen peroxide to water (Lubos et al., 2011).  
 While a definitive role for GSH in azole-associated hepatotoxicity has not been 
established, GSH depletion is essential to the pathogenesis of one of the best characterized 
hepatotoxicities, that caused by acetaminophen (APAP). In APAP toxicity, GSH is depleted by 
the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) generated by CYP metabolism, 
causing oxidative stress and cell damage. The GSH precursor N-acetylcysteine (NAC) is the 
treatment of choice for this toxicity in veterinary medicine (Webster and Cooper, 2009).  
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Rodriguez and Buckholz (2003) demonstrated a time dependent decrease in hepatic GSH 
in rats administered 90 mg/kg of KTZ. Because this decrease in GSH occurred hours after 
administration, the authors hypothesized that reactive KTZ metabolites (DAK and N-hydroxy-
DAK) rather than the parent compound may bind to and deplete GSH. In this way, GSH may 
play a role in detoxification of KTZ via metabolite conjugation. If GSH is further depleted due to 
oxidative stress, then conjugation and removal of metabolites may be decreased, leading to 
subsequent liver injury.  
 Others, however, have proposed that GSH does not play a role in detoxification of ITZ. 
Rats administered ITZ and curcumin, an antioxidant that increases glutathione S-transferase 
(GST) activity in the liver (Piper et al., 1998), had no significant change in cytotoxicity (Somchit 
et al. 2009), suggesting that GSH may not be involved in detoxification of ITZ. Additional 
research is required to better understand what role GSH plays in ITZ-associated hepatotoxicity.  
 
Hepatoprotectants  
 Hepatoprotectants are commonly used in veterinary medicine to treat a variety of liver 
injuries. They include the GSH precursors S-adenosyl-L-methionine (SAMe) and N-
acetylcysteine (NAC) as well as the antioxidants silybin, vitamin E, and vitamin C. Their use is 
best described in inflammatory diseases and specific toxicities, like APAP and Amanita 
mushroom toxicity (Webster and Cooper, 2009). Hepatoprotectants are often used in cases of 
suspected azole-induced hepatotoxicity with anecdotal success, however, no scientific studies 
have been performed to date to support their use.  
S-adenosyl-L-methionine  
 S-adenosyl-L-methionine (SAMe) (Figure 1.4) is formed from methionine and adenosine 
triphosphate (Bottiglieri, 2002). It is an endogenous molecule serving as an essential methyl 
donor and precursor for aminopropylation pathways and the synthesis of GSH (Bottiglieri, 
2002). The product of methylation reactions involving SAMe is S-adenosylhomocysteine (SAH), 
which is further converted to adenosine and homocysteine by SAH hydrolase (Mato et al., 1997). 
Homocysteine then is either remethylated to form methionine or undergoes transsulfuration to 
form cystathionine, followed by hydrolysis to α-ketobutyrate and cysteine (Lieber and Packer, 
2002). Cysteine, the rate-limiting factor in GSH synthesis, goes through two sequential 




Figure 1.4. Chemical structure of SAMe (Lu et al., 2000) 
 
 
Figure 1.5. Synthesis and metabolism of SAMe (Lu et al., 2000) 
 
 The role of SAMe in non-alcoholic steatohepatitis (NASH) and alcohol induced liver 
injury in humans has been extensively investigated. In rodents chronically administered ethanol, 
SAMe administration increases liver GSH concentrations and reduces liver injury (Feo et al., 
1986, Song et al., 2003). In a randomized, multicenter clinical trial, SAMe treatment in patients 
with alcoholic liver cirrhosis improved survival or delayed liver transplantation (Mato et al., 
1999). Similarly, hepatic SAMe levels are decreased in experimental rodents models of NASH 
(Wortham et al., 2008). SAMe has also been used in man to treat drug-induced liver injury. For 
example, patients treated with bevacizumab and oxaliplatin for colorectal cancer in addition to 
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SAMe had significantly lowered ALT, AST, GGT, and bilirubin compared to those receiving the 
chemotherapeutic alone (Vincenzi et al., 2012).  
 The effects of SAMe administration has been evaluated in dogs and cats. In healthy cats, 
SAMe increased hepatic GSH and improved the redox status of both the liver and erythrocytes 
(Center et al., 2005a). Dogs administered oral prednisone and SAMe had increased hepatic GSH 
and improved hepatic antioxidant status, but no changes in clinical or histologic signs of 
vacuolar hepatopathy (Center et al., 2005b). SAMe also protects erythrocytes from oxidative 
damage in experimental acetaminophen toxicity (Webb et al., 2003) and has been used to 
successfully treat acetaminophen toxicity in a dog (Wallace et al., 2002). The chemotherapeutic 
lomustine (CCNU) causes hepatic toxicity in 6.1% of dogs (Kristal et al., 2004) and elevated 
ALT in up to 84% of treated dogs through unknown mechanisms (Skorupski et al., 2011). In a 
clinical trial by Skorupski et al. (2011), dogs administered Denamarin ®, a combination SAMe 
and silybin product used in dogs and cats, concurrently with CCNU had significantly decreased 
ALT, AST, ALP, and bilirubin compared to dogs receiving CCNU alone. These examples 
demonstrate the utility of SAMe with or without silybin in preventing and/or treating drug-
induced hepatic injury in dogs and cats.     
 Few in vitro studies are published examining the effects of SAMe in canine hepatocytes. 
Au et al. (2012) exposed canine primary hepatocytes to a combination of SAMe and silybin (see 
below) and interleukin 1β (IL-1β). The cells had decreased production of inflammatory 
mediators, including IL-8, monocyte chemotactic protein-1 (MCP-1), and prostaglandin E2 
(PGE2) compared with hepatocytes treated with IL-1β alone. Additionally, hepatocytes treated 
with IL-1β had decreased intracellular levels of GSH, which was restored to control levels with 
addition of SAMe and silybin. This study shows the combined antioxidant and anti-inflammatory 
effects of SAMe and silybin in canine hepatocytes.  
N-acetylcysteine 
 N-acetylcysteine (NAC), a variant of the amino acid L-cysteine and precursor of GSH, is 
an antioxidant that scavenges endogenous free radicals such as hypochlorous acid and hydroxyl 
radical (Aruoma et al., 1989). Animal models have demonstrated NAC’s efficacy in treating 
hepatotoxicity, acute liver failure, ischemia-reperfusion injury, and improving microcirculation 
in bile duct obstruction (Zafarullah et al. 2003; Lee et al., 2009; Smyrniotis et al., 2005; Kigawa 
et al., 2000). Its use and efficacy are best characterized in APAP-induced toxicity (Zafarullah et 
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al., 2003), where it is considered the treatment of choice in small animals (Webster and Cooper, 
2009; Aronson and Drobatz, 1996; Villar et al., 1998) and man (Heard, 2008). NAC restores 
reduced GSH levels in the cell, allowing detoxification of the toxic NAPQI metabolite 
(Lauterburg et al., 1983). NAC has also been effective in treating non-APAP associated acute 
liver failure caused by other drugs, infections, or autoimmune conditions (Lee et al., 2009). 
 NAC provides a protective effect against hepatotoxicity caused by cyclosporine A in rats 
(Kaya et al., 2008), arsenic in mice (Santra et al., 2007), and azathioprine in rat hepatocytes 
(Menor et al., 2004). Kaya et al. demonstrated decreased activity of endogenous antioxidants in 
cyclosporine A treated rats. Both Santra et al. and Menor et al. demonstrated reduced hepatic 
GSH after exposure to arsenic and azathioprine, respectively, and partial restoration of GSH 
levels with administration of NAC. As described previously, there is evidence of GSH depletion 
and oxidative stress in rodent models of KTZ and ITZ hepatotoxicity, so administration of NAC 
may ameliorate these effects. To date, there are no published studies examining the effect of 
NAC on azole-induced hepatotoxicity.  
Silybin  
 Silybin is one of seven flavonolignans that makes up silymarin, a component of the milk 
thistle plant (Boothe, 2012). Silybin has antioxidant (Bosisio et al., 1992; Carini et al., 1992; 
Trouillas et al., 2008), anti-inflammatory (Bremner and Heinrich, 2002; Gharagozloo et al., 
2010), and anti-fibrotic (Lieber et al., 2003) effects. However, in humans with chronic liver 
disease, evidence of clinical efficacy is lacking (Loguercio and Festi, 2011). In acute liver 
damage, silybin has been associated with increased survival in adults and children exposed to the 
toxic mushroom Amanita phalloides (Enjalbert et al., 2002) and was protective against 
intoxication in Beagle dogs experimentally administered A. phalloides (Vogel et al., 1984). It has 
also been used in combination with SAMe to prevent CCNU-associated hepatopathy in dogs 
(Skorupski et al., 2011).  
 Multiple experimental studies demonstrate the anti-inflammatory and antioxidant effects 
of silybin. Au et al. showed that canine hepatocytes exposed in vitro to IL-1β had increased 
production of the inflammatory mediators PGE2, IL-1, and MCP-1, which was inhibited by 
administration of silybin (Au et al., 2011). In a study demonstrating the potential beneficial 
effects of silybin on ITZ-induced hepatotoxicity, rats administered a combination of ITZ and 
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silybin had decreased nitric oxide, myeloperoxidase, ALT, and AST levels compared to rats 
administered ITZ alone (Sozen et al., 2014). This study demonstrates a potential use for silybin 
in ITZ-associated hepatotoxicity in other species.  
Vitamin E and Vitamin C 
 Vitamin E is a lipid soluble tocopherol existing in four isomers, the most biologically 
active of which is α-tocopherol (Van Metre and Callan, 2001). This tocopherol is a potent 
antioxidant that scavenges lipid peroxyl radicals, protecting cell membranes from oxidative 
damage (Jiang, 2014). Vitamin E therapy in human patients with NASH has shown modest 
improvement in liver enzyme tests (El Hadi et al., 2018). In a rodent study examining the effects 
of vitamins on APAP toxicity, pretreatment with vitamin E reduced hepatic oxidative stress 
(Abdulkhaleq et al., 2018). 
 Vitamin C has myriad functions, including improving immune function, facilitating 
enteric absorption of non-heme iron, synthesizing collagen, and acting as an antioxidant 
(Oudemans-van Straaten et al., 2014). As a hepatic antioxidant, vitamin C has beneficial effects 
on ischemia-reperfusion injury and endotoxin-induced oxidative damage (Seo and Lee, 2002; 
Cadenas et al., 1998). 
Combination therapy of vitamin E and vitamin C in a prospective, randomized study of 
45 adults improved fibrosis scores in patients with NASH (Harrison et al., 2003). Another 
randomized study of 247 adults with NASH had decreased serum ALT and AST, decreased 
steatosis and inflammation, but no change in fibrosis (Sanyal et al., 2010). Rodent studies of 
APAP toxicity have demonstrated that pretreatment with vitamins C, E, and B12 reduced hepatic 
oxidative stress. Vitamin C was more effective than vitamins E and B12 and in vitro hepatocyte 
survival was highest with combination therapy of all three (Abdulkhaleq et al., 2018). Treatment 
with vitamin E, vitamin C, or a combination of both has beneficial effects in liver diseases 
associated with oxidative damage in humans and animals and thus may be beneficial in animals 
receiving ITZ therapy.   
 
Conclusion 
Systemic azole antifungals are an essential component of a veterinary practitioner’s 
antimicrobial arsenal. The newer triazole antifungals, including ITZ, FCZ, voriconazole, and 
posaconazole, are more effective and associated with fewer side effects when compared to KTZ 
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and non-azole antifungals. ITZ has a broad spectrum of action and is the first line treatment of 
choice for canine blastomycosis and other systemic mycoses. Unfortunately, all azoles are 
associated with hepatic and non-hepatic adverse drug reactions. Hepatic reactions can lead to 
interruption in therapy, significant illness, and even death.  
In man, hepatic CYP3A4 is responsible for metabolism of ITZ into numerous 
metabolites. While a similar pathway is suspected in dogs, the responsible enzyme(s) has not 
been identified. Based on in vitro rodent studies, CYPs are not responsible for production of 
toxic metabolites (Somchit et al., 2002). Either the toxicity is induced by the parent drug or 
metabolites are produced via alternate pathways, such as the FMO-mediated pathway which 
generates toxic metabolites from KTZ. Regardless of the exact toxic principle, oxidative damage 
occurs during ITZ-associated hepatotoxicity (Sozen et al., 2014; El-Shershaby et al., 2015). This 
oxidative damage may be alleviated by supplementation with hepatoprotectants. These include 
GSH precursors like SAMe and NAC and antioxidants such as silybin, vitamin C, and vitamin E. 
The utility of antioxidants in canine ITZ-associated hepatotoxicity is unknown. The goal of this 




CHAPTER 2: THE EFFECT OF GLUTATHIONE ON ITRACONAZOLE-
ASSOCIATED HEPATOCYTE TOXICITY IN CANINE PRIMARY HEPATOCYTES 
 
Abstract 
Itraconazole (ITZ) is used to treat many types of fungal infections in dogs. However, 
therapy is associated with dose-dependent increases in liver enzymes in up to 42% of dogs. 
Glutathione (GSH) precursors are often used to treat ITZ-associated hepatotoxicity, although no 
studies have investigated their efficacy. The objectives of this study were (1) to develop an in 
vitro model of ITZ-associated hepatotoxicity in canine primary hepatocytes and (2) to identify 
the effect of GSH on cell death in hepatocytes exposed to ITZ. We hypothesized that canine 
primary hepatocytes would be an appropriate model for this hepatotoxicity and that GSH 
treatment would decrease cell death. 
During model development in the first objective, three different cell viability assays were 
tested, including calcein AM, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), and neutral red. Using a sandwich culture technique, canine primary hepatocytes were 
incubated with 5-fold dilutions of ITZ (0 to 50 µM) for 4 hours. Cells were plated at a 
concentration of 5.0 x105 cells/ml (calcein AM) or 2.4x105 cells/ml and 0.8 x105 (MTT and 
neutral red). Neutral red was the only assay that detected the expected dose-dependent 
cytotoxicity. The cells maintained optimum viability at a seeding concentration of 2.4x105 
cells/ml, so this concentration was selected for future experiments. Hepatocyte phenotype was 
assessed by measurement of albumin production using an enzyme-linked immunosorbent assay 
(ELISA) for canine albumin and morphologic assessment via phase contrast microscopy. 
Maintenance of hepatocyte phenotype was confirmed by continued production of albumin and 
retention of cell morphology over time. 
For the second objective, canine primary hepatocytes were incubated for 24 hours with 
10-fold dilutions of GSH (0 to 500 µM) and then exposed to 5-fold dilutions of ITZ (0 to 50 
µM). Cell function was determined by assessing urea production and cell viability was 
determined using the neutral red assay after 4 and 24 hours of ITZ exposure (n=3). A 
colorimetric urea assay kit did not detect a significant change in urea production with increasing 
ITZ concentration, time, or GSH concentration. The effect these three factors on cytotoxicity was 
assessed using multivariate linear regression. Hepatocyte cytotoxicity significantly increased 
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with ITZ concentration (p<0.001) and time (p=0.004) and significantly decreased with GSH 
treatment (p<0.001).  
Using canine primary hepatocytes plated at 2.4x105 cells/ml in a sandwich culture, we 
demonstrated dose- and time-dependent ITZ-associated cytotoxicity. Pre-treating with GSH 
provided a protective effect against cell death. These results suggest that GSH precursors may 
have a role in the management or prevention ITZ-associated hepatotoxicity in dogs. Clinical 
trials are needed to evaluate their utility for this adverse drug reaction. 
 
Introduction 
Itraconazole (ITZ) is an azole antifungal drug used to treat a wide variety of fungal 
infections in dogs, including both superficial cutaneous infections such as dermatophytosis and 
malasseziosis, and systemic mycoses such as blastomycosis and histoplasmosis (Greene, 2012). 
The azoles’ antifungal activity is attributable to inhibition of ergosterol by targeting the 
cytochrome P450-dependent sterol 14α-demethylase (Vanden Bossche, 1985). The most 
commonly used azoles in veterinary medicine are ITZ, fluconazole, and ketoconazole. ITZ is 
more selective than ketoconazole, leading to fewer side effects, and has a broader spectrum of 
action than both ketoconazole and fluconazole (Van Cutsem et al., 1987a; Van Cutsem et al., 
1990). Additionally, ITZ is more efficacious than ketoconazole in treating a variety of fungal 
infections in animal models (Van Cutsem et al., 1987b; Van Cutsem et al., 1987c).  
ITZ is the treatment of choice for canine blastomycosis, which is endemic in the 
Midwestern United States, with a reported cure rate of 54-90% and a relapse rate of 18-20% 
(Legendre et al., 1996; Mazepa et al., 2011). Despite its efficacy, ITZ is associated with a 
number of adverse reactions in dogs including nausea, vomiting, lethargy, anorexia, ulcerative 
dermatitis with vasculitis, and hepatotoxicity (Legendre et al., 1996; Mazepa et al., 2011). 
Anorexia is most common and may be associated with increases in alanine aminotransferase 
(ALT) (Legendre et al., 1996). Increases in ALT are reported in 12-42% of dogs depending on 
the dose and duration of treatment (Legendre et al., 1996; Mazepa et al., 2011; Wilson et al., 
2018). Based on clinical experience, clinical hepatotoxicity does occur, although the prevalence 
in dogs is not reported. In a systemic review and meta-analysis of humans experiencing similar 
adverse reactions to ITZ, the pooled risk of developing abnormal liver function tests 
necessitating discontinuation of treatment was 1.5% (Wang et al., 2010). Although drug 
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discontinuation generally results in reversal of these changes in dogs, switching antifungal drugs 
can negatively affect the course of the mycosis if alternative drugs are less effective or result in 
their own adverse reactions. 
As with many adverse drug reactions, oxidative damage may play an important role in 
ITZ-associated toxicity. Rodent models demonstrate increases in reactive oxygen species as well 
as decreases in antioxidant enzymes and glutathione (Sozen et al., 2014; El-Shershaby et al., 
2015). Glutathione (GSH) is an endogenous hepatic antioxidant that is essential for maintenance 
of redox potential, cell signaling, and survival (Yuan and Kaplowitz, 2009). These experimental 
findings suggest that GSH supplementation and antioxidant therapy may be beneficial in treating 
or preventing ITZ-associated toxicity in animals.  
Commonly used hepatoprotectants in veterinary medicine, including S-adenosyl-L-
methionine (SAMe) and N-acetylcysteine, are important in the synthesis and maintenance of 
cellular GSH levels (Bottiglieri, 2002; Lauterburg et al., 1983). SAMe, N-acetylcysteine, and 
other antioxidants like silybin, α-tocopherol (vitamin E), and ascorbic acid (vitamin C) are 
commonly used in dogs with clinical changes consistent with ITZ-associated hepatotoxicity. 
However, no studies have investigated the efficacy of this practice. Because many of these 
products are expensive and can cause inappetence, scientific evidence is needed to provide a 
basis for their rational use. The first objective of this work was to develop an in vitro model of 
ITZ-associated hepatotoxicity using cryopreserved canine primary hepatocytes. The second 
objective was to evaluate the effect of GSH treatment on ITZ-associated hepatotoxicity using the 
newly established model. We hypothesized that canine primary hepatocytes would be an 
appropriate model of ITZ-associated hepatotoxicity and that GSH treatment would decrease cell 
death.  
 
Materials and Methods  
Objective 1: Assay Development 
Cell Culture 
Unless otherwise noted, all materials and reagents were obtained from ThermoFisher 
Scientific (Waltham, MA). Cryopreserved male dog (Beagle) primary hepatocytes from a single 
donor (Catalog number: DGCP10; Lot number: DB343) were thawed in a 37° Celsius (C) water 
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bath for <2 minutes and resuspended in 50 mL of thawing/plating medium (William’s E medium 
with 5% fetal bovine serum, 1 uM dexamethasone in dimethyl sulfoxide (DMSO), 1% 
penicillin/streptomycin, 4 ug/ml human recombinant insulin, 2 mM GlutaMAX, and 15 mM 
HEPES at pH 7.4). Following resuspension, the cells were centrifuged at 60 x g for 4 minutes 
and counted using a hemocytometer and the Trypan Blue dye exclusion method. The cells were 
then plated into pre-collagen I coated, sterile culture plates and incubated at 37°C for 4 hours. 
After incubation, the supernatant was discarded and cold extracellular matrix gel from 
Engelbreth-Holm-Swarm murine sarcoma (Sigma-Aldrich, St. Louis) diluted to 0.35 mg/mL in 
incubation medium (William’s E medium with 0.1 uM dexamethasone in DMSO, 0.5% 
penicillin/streptomycin, 6.25 ug/mL human recombinant insulin, 6.25 ug/mL human transferrin, 
6.25 ng/mL selenous acid, 1.25 mg/mL bovine serum albumin, 5.35 ug/mL linoleic acid, 2 mM 
GlutaMAX, and 15 mM HEPES at pH 7.4,) was applied over the cells prior to an overnight 
incubation at 37°C.  
Maintenance of Cell Phenotype 
To determine maintenance of biochemical phenotype, cryopreserved canine primary 
hepatocytes plated as described above were incubated for 24, 48, or 72 hours. No-cell wells were 
included as controls. At each time point, supernatants were collected and frozen at -80°C. Frozen 
supernatants were later thawed on ice and albumin levels determined using a canine-specific 
albumin enzyme linked immunosorbent assay kit according to manufacturer’s instructions (Eagle 
Biosciences; Amherst, NH). Absorbance was quantified using a SpectraMax iD3 multi-mode 
microplate reader and SoftMax Pro 7 software (Molecular Devices; San Jose, CA). To determine 
maintenance of cellular morphology, cells were examined for polygonal morphology and the 
presence of cell-to-cell junctions using Invitrogen EVOS XL Core Cell Imaging System 
(ThermoFisher Scientific; Waltham, MA) at 24, 48, and 72 hours of incubation. Albumin 
production and morphologic features were selected as they are commonly evaluated when 
assessing hepatic phenotype (Ware et al., 2018). 
Cell Viability Assay Optimization  
Three viability assays were trialed during model development: calcein AM, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and neutral ted. For these tests, 
cells were cultured as described above and exposed to 0, 2, 10, or 50 µm ITZ diluted in DMSO 
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for 4 hours. DMSO concentration was below 1% for all treatments. Cells were plated at a 
concentration of 5.0 x105 cells/ml (calcein AM) or 2.4x105 cells/ml and 0.8 x105 cells/ml (MTT 
and neutral red). A SpectraMax iD3 multi-mode microplate reader and SoftMax Pro 7 software 
were used to measure absorbance (O.D.) or fluorescence (RFUs) depending on the assay. Each 
condition was performed in technical triplicate and % cytotoxicity calculated as: 
 
% cytotoxicity =   �1 −  
mean valuetreatment −  mean valueblank
mean valueno ITZ −  mean valueblank
�  x 100% 
 
The first assay tested was calcein AM, which is a non-fluorescent permanent dye that 
permeates live, intact cells. Cytosolic esterases hydrolyze calcein AM into the fluorescent 
molecule calcein (Weston and Parish, 1990). Following incubation with ITZ, the cells were 
washed with incubation medium and incubated with diluted calcein AM cell-permanent dye 
(ThermoFisher Scientific; Waltham, MA) at 37° C for 30 minutes. Then, the cells were washed 
again and fluorescence measured at an excitation wavelength of 485 nm and emission 
wavelength of 525 nm. 
The second assay tested was 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (ThermoFisher Scientific; Waltham, MA). MTT is reduced by a metabolically 
active cell into insoluble formazan via mitochondrial NADPH oxidoreductase (Stockert et al., 
2018). Following incubation with ITZ, the cells were washed and incubated with diluted MTT at 
37° C for 4 hours. Formazan was then solubilized by the addition of 0.1% DMSO and 
absorbance measured at 590 nm.  
Lastly, neutral red dye uptake into lysosomes was measured using a neutral red cell 
cytotoxicity assay kit (BioVision; Milpitas, CA) according to the manufacturer’s instructions. 
Viable cells release the dye into the supernatant after solubilization, which is then measured at an 
absorbance of 540 nm. 
Objective 2: The effect of GSH on ITZ-associated cytotoxicity 
Exposure of cells to ITZ and GSH 
Following plating and overnight incubation with the ECM gel overlay, cells were pre-
treated with 0, 50, or 500 µM of GSH (Sigma-Aldrich; St. Louis, MO) diluted in incubation 
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medium and incubated for 24 hours. These concentrations were based on GSH concentrations 
previously detected in canine livers (Dedeaux et al., 2020). The cells were then exposed to 0, 2, 
10, or 50 µM ITZ (Sigma-Aldrich; St. Louis, MO) diluted in DMSO for 4 or 24 hours. These 
concentrations were chosen based on plasma drug concentration that occur during therapeutic 
dosing of ITZ in dogs with significant intrahepatic accumulation expected (Mawby et al., 2013; 
FDA 1992). No-cell controls were included as blanks. 
The neutral red cell cytotoxicity assay was used to determine cell viability at 4- and 24-
hours post ITZ exposure. Following staining and dye solubilization, the absorbance was 
quantified and cytotoxicity calculated as described for objective 1. Each condition was 
performed in technical triplicate. 
Urea assay 
Urea is produced by hepatocytes from ammonia as the end product of protein catabolism. 
When hepatocytes are damaged, urea production decreases (Watson, 2014). For this reason, urea 
was chosen as a measure of hepatic dysfunction and possible sublethal damage in hepatocytes 
exposed to ITZ. Supernatants were removed from treatment wells after exposure to GSH and 
ITZ (see Exposure of cells to ITZ and GSH section) prior to assessment of cell viability and 
frozen at -80° C. Urea was measured in thawed supernatants using a colorimetric urea assay kit 
(Abnova; Taipei, Taiwan) according to the manufacturer’s instructions.  
Statistical Analysis  
Based on both clinical evidence in dogs and experimental rodent studies (Somchit et al., 
2002; Somchit et al., 2009), viability assay selection in objective 1 was based on demonstration 
of dose-dependent cytotoxicity in cells exposed to ITZ. The optimal cell concentration was 
chosen for wells in which viability and dose-dependent cytotoxicity were maintained. For 
maintenance of phenotype testing, an unpaired t-test was used to compare albumin production by 
hepatocytes and media control wells. A one-way ANOVA was used to evaluate the effect of time 
on albumin production. Changes in cellular morphology were assessed qualitatively. For 
objective 2, the effect of time, GSH concentration, and ITZ concentration on % cytotoxicity was 
assessed using a multivariate linear regression model. Similarly, a multivariate linear regression 
model was used to determine the effect of these three factors on urea production. All analyses 
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were performed using commercial software (Prism 8, GraphPad Software, San Diego, CA; JMP 
14, SAS Institute, Cary, NC). Statistical significance was set at p < 0.05. 
 
Results 
Objective 1: Assay Development 
Maintenance of hepatic phenotype  
Albumin was detectable at all time points in significantly greater amounts than controls 
(p < 0.001). Albumin production decreased significantly over time (p=0.0045) (Figure 2.1). 
Hepatocytes maintained cell-to-cell adhesion and their expected polygonal morphology at all 
time points (Figure 2.2).  
 
Figure 2.1. Albumin concentration (ng/ml) in supernatant of untreated hepatocytes on days 1, 2, 
and 3 of the experiment. Albumin production was significantly greater than controls (p<0.001) at 





Figure 2.2. Phase contrast microscopy of untreated hepatocytes at 24 hours (A), 48 hours (B), 
and 72 hours (C) of incubation. The cells maintained cell-to-cell adhesion (arrows) and the 
polygonal morphology characteristic of hepatocytes. 
Cell viability assay optimization 
The results of cell viability optimization are presented graphically in Figure 2.3. A dose-
dependent increase in hepatocyte cytotoxicity was not detected after 4 hours of ITZ exposure 
using calcein AM or MTT assays. In contrast, dose-dependent cytotoxicity was detected after 4 
hours of ITZ exposure using the neutral red assay. For both the MTT and neutral red assays, 




      
 
Figure 2.3. Percent cytotoxicity of hepatocytes treated with ITZ for 4 hours and viability 
detected using (A) calcein AM, (B) MTT, or (C) neutral red dyes.  
 
Objective 2: The effect of GSH on ITZ-associated cytotoxicity 
Exposure of cells to ITZ and GSH 
Cytotoxicity results are graphically presented in Figure 2.4. Hepatocyte cytotoxicity 
significantly increased with time (p = 0.004) and ITZ concentration (p < 0.001). Cytotoxicity 
significantly decreased with increasing GSH concentration (p < 0.001). A significant interaction 
was identified between time and ITZ concentration (p = 0.014). No other significant interactions 





Figure 2.4. Percent cytotoxicity of hepatocytes treated with GSH and ITZ (A) 4 hours and (B) 
24 hours after ITZ exposure. 
 
Factor/Interaction P-Value 
ITZ < 0.001 
Time 0.004 
GSH < 0.001 
ITZ x Time 0.014 
ITZ x GSH 0.980 
Time x GSH 0.306 
ITZ x Time x GSH 0.999 
 
Table 2.1. Results of multivariate linear regression analysis for % cytotoxicity with the factors 
ITZ concentration, time, and GSH concentrations. The effect of all three individual factors on % 
cytotoxicity was significant. A significant interaction was observed between ITZ and time, but 
not between GSH and ITZ, GSH and time, or all three factors together. 
Urea assay  
The amount of urea produced by hepatocytes is represented graphically in Figure 2.5. 
Urea production did not significantly decrease with increasing ITZ concentration (p=0.9880) nor 
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did it significantly increase with increasing GSH concentration (p=0.9300). Urea production 
significantly increased over time (p<0.001) (Table 2.2).  
 
 
Figure 2.5. Urea (mg/dL) production in hepatocytes treated with GSH and ITZ for 4 hours (A) 







Table 2.2. Results of multivariate linear regression analysis for urea production with the factors 
ITZ concentration, time, and GSH concentrations. The only significant factor was time.  
 
Discussion 
In the first objective of this study, we showed that cryopreserved canine primary 
hepatocytes in a sandwich culture are an appropriate in vitro model for canine ITZ-associated 
hepatotoxicity. Over the course of 72 hours, cells maintained lineage-specific albumin 
production and morphologic features, thus confirming maintenance of hepatocyte phenotype 
over the course of the experiment. Albumin production did decrease over time, which is likely 
due to decreasing viability rather than dedifferentiation as the cells maintained hepatic 
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morphology. Detection of cell death was best accomplished by measuring the uptake of neutral 
red dye by viable cells. Using this detection method, ITZ caused significant dose- and time-
dependent cytotoxicity in vitro, which mimics the dose-dependent hepatotoxicity seen in vivo 
(Legendre et al., 1996). Similar results have also been demonstrated in rodent models (Somchit 
et al., 2002; Somchit et al., 2009). The second objective of this study investigated the potential 
cytoprotective role of GSH in canine ITZ-associated hepatotoxicity. Pre-treatment of the cells 
with GSH for 24 hours prior to ITZ exposure had a significant dose-dependent protective effect 
against ITZ-associated cytotoxicity. These results suggest that GSH or its precursors may play a 
role in preventing or treating this toxicity in vivo.  
 During the model development stage, we investigated three different markers of cell 
viability. These included calcein AM, a dye that is converted into a fluorescent molecule in live 
cells, and two colorimetric assays, MTT and neutral red. MTT is a salt that is converted into 
formazan in metabolically active cells and neutral red is a dye that is actively incorporated into 
lysosomes. Cells were plated at 5.0 x105 cells/ml for the calcein AM assay per the 
manufacturer’s instructions and at 2.4 x105 cells/ml and 0.8 x105 cells/ml for the MTT and 
neutral red assays. Viability was markedly decreased at the lowest concentration, likely as a 
result of low signal detection. Based on this, a plating concentration of 2.4x105 cells/ml was 
selected for subsequent assays as a balance between viability and conservation of resources. Of 
the three viability assays, only neutral red yielded reproducible results depicting a dose-
dependent increase in hepatocyte toxicity after 4 hours of ITZ exposure. Therefore, we elected to 
use neutral red dye uptake as a measure of cell viability to investigate the role of GSH in 
mitigating cell death.   
The dose-dependent protective effect provided by GSH was most pronounced at the 4-
hour time point; at 24 hours, there was minimal difference between the 50 µM and 500 µM GSH 
groups. The reason for this is unknown, but it is possible that by the end of the experiment, the 
cells had reached their maximum capacity to uptake or respond to GSH regardless of the amount 
provided. The protective effect was also seen in vehicle control cells, which likely experienced 
some cytotoxicity attributable to the toxic effects of the DMSO vehicle (Sumida et al., 2011). 
Reactive oxygen and nitrogen species can accumulate due to a number of cellular insults, so it is 
expected that GSH, the most abundant hepatic antioxidant, would have a protective effect against 
cellular stress of any cause, whether by ITZ or the vehicle control.  
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The protective effect of GSH suggests that oxidative damage may play a role in the 
mechanism of ITZ-associated hepatotoxicity. GSH precursors such as SAMe and N-
acetylcysteine are frequently used as hepatoprotectants in veterinary medicine. Other 
antioxidants, including silybin, α-tocopherol, and ascorbic acid, are also used treat canine liver 
disease. SAMe and silybin in particular have been shown to increase hepatic GSH and decrease 
the production of pro-inflammatory mediators in vitro (Au et al., 2010, Au et al., 2012). The 
beneficial effect of GSH demonstrated here provides evidence for the rational use of 
hepatoprotectants in dogs with suspected ITZ-induced hepatotoxicity and may also provide 
insight into mechanisms of toxicity, which are poorly understood. Hepatic oxidative damage has 
been demonstrated in rodent models of ITZ-induced hepatotoxicity, indicating a potential role 
for depletion of GSH and other antioxidants (Sozen et al., 2014; El-Shershaby et al., 2015). GSH 
could be directly involved in detoxification by binding toxic metabolites, which has been 
proposed in ketoconazole-mediated hepatotoxicity (Rodriguez and Buckholz 2003). 
Alternatively, it is possible that depletion of antioxidants occurs by another mechanism such that 
GSH supplementation improves cellular antioxidant status and, thus, viability.  
This study sets the groundwork for additional investigation into the use of antioxidants in 
ITZ-associated hepatotoxicity in dogs. There are, however, some limitations to these in vitro 
experiments. Hepatocytes were pre-incubated with GSH to achieve maximum effect despite pre-
treatment not being a practical expectation in dogs requiring immediate antifungal therapy. 
However, daily co-administration of GSH precursors with ITZ in vivo is expected to provide a 
long-term effect over time. Additionally, canine primary hepatocytes were obtained from a single 
donor, which does not take into account inter-individual variability. To address this, future 
studies will assess pharmacogenetic variation in vivo.   
Urea production was measured in an attempt to account for sublethal damage, which is 
another possible outcome of ITZ therapy. Urea is a marker of hepatocyte function, so we 
hypothesized that cells exposed to ITZ would have a dose-dependent decrease in urea 
production, which would be mitigated by the addition of GSH. However, contrary to the results 
from cytotoxicity experiments, a dose dependent decrease in urea production in hepatocytes 
exposed to ITZ was not detected and GSH supplementation did not mitigate this effect. There are 
several possible explanations for this discrepancy. First, the timing of supernatant collection 
allowed urea to accumulate from when the cells were plated until the end of the experiment at 
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either 4- or 24-hours post-exposure to ITZ. This explains why urea production significantly 
increased over time. The accumulation of urea over time may have masked subtle changes in 
production. This could be addressed in the future by washing the cells 4 hours prior to 
supernatant collection to allow a consistent time frame for urea to accumulate. If this protocol 
alteration does not produce the expected results, then using an alternative urea kit through a 
different manufacturer may be required. It is also possible that endogenous urea production is not 
a useful functional marker in this particular model, so other tests like albumin production could 
be assessed. Indeed, we demonstrated albumin production by the cells when assessing hepatic 
phenotype, so this assay could be used as a measure of function in future experiments.  
Another limitation inherent to all in vitro experiments is that our results may not reflect in 
vivo biologic behavior in dogs experiencing clinical ITZ-associated hepatotoxicity. To address 
this concern, several features of our assay were specifically designed to best mimic the in vivo 
environment. Primary hepatocytes were chosen for this study over immortalized cells because 
they maintain liver-specific functions and enzyme activity that more accurately represent in vivo 
function (Hewitt et al., 2007; Guo et al., 2011). We also chose a sandwich configuration where 
cells are cultured between two layers of collagen. This is the preferred method for in vitro drug 
disposition and hepatotoxicity studies (Keemink et al., 2015). Compared to cells cultured on a 
single layer of collagen, sandwich-cultured hepatocytes produce albumin for longer, maintain 
their polygonal morphology (Dunn et al., 1989), and repolarize to form bile canaliculi (LeCluyse 
et al., 1994; Bi et al., 2006), thus more closely reflecting their in vivo functionality. These 
findings have been consistently demonstrated in fresh, sandwich-cultured rat (LeCluyse et al., 
1994; Dunn et al., 1989) and dog (Rose et al., 2006) hepatocytes as well as cryopreserved human 
hepatocytes (Bi et al., 2006).  
Future in vitro studies will assess additional antioxidants (ascorbic acid and α-tocopherol) 
to select the most effective compound prior to clinical trials in canine patients. Results of this 
and future studies are critical to developing guidelines for the use of antioxidants in ITZ-
associated hepatotoxicity in dogs. Additional studies are underway in our laboratory to determine 
how ITZ is metabolized in dogs and the possible contribution of genetics in predicting this drug 
reaction. Between breed and within breed polymorphisms are responsible for a number of 
differences in drug metabolism. A classic example is ivermectin sensitivity in collie dogs where 
a deletion in the multidrug resistance gene encoding for the efflux pump P-glycoprotein results in 
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neurotoxicity (Mealey et al., 2001). Others involve differences in CYP enzymes. In Greyhound 
dogs, CYP2B11 deficiency has been implicated in poor clearance of the anesthetic propofol. 
Recently, three CYP2B11 haplotypes were identified across 63 dog breeds; a specific haplotype 
in Greyhounds was associated with reduced CYP2B11 expression (Martinez et al., 2020). These 
examples highlight the importance of first identifying the enzyme responsible for ITZ 
metabolism and then screening dogs for genetic polymorphisms that may predict hepatotoxicity.  
In this study, we showed that ITZ causes dose- and time-dependent hepatocyte toxicity in 
vitro. These findings demonstrate that appropriately cultured canine primary hepatocytes are a 
viable model in which to study ITZ-associated hepatotoxicity in dogs. Most importantly, ITZ-
induced cytotoxicity is mitigated by pre-incubation with GSH in a dose-dependent manner, 
suggesting a possible role for GSH or its precursors in the management of ITZ-associated 




CHAPTER 3: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Hepatotoxicity associated with the use of azole antifungals is a serious potential treatment 
complication in both veterinary species and man. While ITZ and other triazole antifungals are 
associated with fewer adverse reactions when compared with KTZ, these reactions do occur and 
can lead to a delay in therapy or significant morbidity and mortality. The mechanism of 
hepatotoxicity in dogs is unknown. In Chapter 2, we demonstrated that GSH exerts a dose-
dependent protective effect against ITZ-associated cytotoxicity in canine primary hepatocytes. 
GSH is the most abundant hepatocellular antioxidant and is responsible for maintaining redox 
potential and cell signaling. Rodent studies have shown increased hepatic oxidative stress and 
decreased levels of GSH and other antioxidants in rats administered ITZ (Sozen et al., 2014; El-
Shershaby et al., 2015). Similar to the study presented in Chapter 2, rats also experience dose- 
and time-dependent ITZ-associated hepatotoxicity in vivo (Somchit et al., 2002; Somchit et al., 
2009). The protective effect provided by GSH in vitro suggests that the clinical use of 
antioxidants in dogs may prevent or alleviate this toxicity. Future in vitro studies in our lab will 
characterize the effects of other antioxidants (ascorbic acid and α-tocopherol) using this model. 
Once the optimum antioxidant has been identified, we will begin clinical trials in canine patients 
receiving ITZ.  
There are many other parameters that could be evaluated in this model. First, the presence 
of sublethal damage could be assessed by measuring ALT in the supernatant. GSH was co-
administered with ITZ in the study presented in Chapter 2; future studies could investigate the 
effect of GSH administered before, with, and after ITZ. This would help direct the timing of 
treatment in clinical situations. Lastly, it is not known if endogenous GSH decreases in canine 
hepatocytes exposed to ITZ. Rodriguez and Buckholz (2003) hypothesized that GSH may play a 
role in KTZ detoxification, so it is possible that progressive GSH depletion may be a mechanism 
of toxicity. If GSH is indeed depleted in vitro, this would establish a plausible mechanistic 
explanation for why supplementation is protective.  
 A vital part of understanding ITZ-associated hepatotoxicity is identifying the major 
pathways of its metabolism in the liver. ITZ is metabolized by CYP3A4 in man. The major 
metabolite, hydroxy-ITZ, has been identified in canine serum (Yoo et al., 2002). Based on this 
information, our laboratory hypothesizes that canine CYP3A12 and/or CYP3A26 are responsible 
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for metabolism in dogs. Studies are underway using canine liver microsomes incubated with ITZ 
to identify what metabolites are produced and what specific CYP(s) is involved using 
commercially available recombinant enzymes. ITZ and its metabolites inhibit CYP3A4 (Back 
and Tija, 1991; Isoherranan et al., 2004), so CYP inhibition in dogs will be assessed using a 
probe known to be metabolized by the enzyme (i.e. diazepam for CYP3A12). Once the 
metabolizing CYP has been established, that enzyme can be depleted in canine hepatocytes in 
vitro followed by exposure to ITZ and viability assessment as outlined in Chapter 2. 
Pharmacogenetic studies in dogs receiving ITZ therapy may identify genetic polymorphisms in 
genes encoding for CYPs that predispose to development of hepatotoxicity.  
 Rodent studies may aid in better understanding ITZ-associated hepatotoxicity. Studies by 
Somchit et al. (2004, 2006) identified varying patterns of hepatic degeneration and necrosis 
caused by ITZ in rats. A study controlling for dose and duration of ITZ treatment will help to 
clarify these divergent morphologic findings. Drug metabolizing enzymes are stratified in the 
liver, causing specific patterns of injury depending on the location of the enzyme. For example, 
if CYP enzymes produce a toxic metabolite, hepatocyte damage is expected to occur where CYP 
enzymes are concentrated (centrilobular regions). Alternatively, if progressive autoinhibition of 
CYP leads to accumulation of the parent compound and subsequent toxicity, damage is expected 
to occur where cells first contact ITZ (periportal regions). Both KTZ and its metabolites have 
been shown to be toxic to rat hepatocytes (Rodriguez and Acosta, 1995; Rodriguez and Acosta, 
1997a), so it is reasonable to hypothesize that mixed periportal and centrilobular damage may 
occur with ITZ toxicity. Correlating the findings of in vitro enzyme and viability assays with 
morphologic changes in the liver will provide evidence that in vitro results are consistent with 
what occurs in vivo.  
 The study discussed in Chapter 2 provides a basis for future in vitro studies to elucidate 
mechanisms of ITZ-associated hepatotoxicity and the effect of antioxidant therapy in dogs. The 
protective effect of GSH identified here establishes that GSH or its precursors may be an 
effective prevention or therapeutic strategy for this toxicity. Future studies in our laboratory will 
explore the effect other antioxidants both in vitro and in clinical trials, investigate mechanisms of 
metabolism and toxicity, and identify potential genetic risk factors in dogs. We hope this work 
will provide veterinary practitioners with rational prevention and treatment strategies of this 
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